Harmony Biosciences Reports Third Quarter 2021 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue of
Average Number of Patients on WAKIX Increased to ~3,500
Announced Inclusion of WAKIX in
Conference Call and Webcast to be Held Today at
“The company continues to execute on optimizing the performance of WAKIX, demonstrated by another solid quarter of sequential revenue growth with an average number of patients on WAKIX of approximately 3,500,” stated
Third Quarter 2021 Financial Results
Net product revenues for the quarter ended
For the quarter ended
Reconciliations of applicable GAAP measures to non-GAAP adjusted information are included at the end of the press release.
The components of Harmony’s operating expenses include:
- Research and Development expenses were
$11.7 millionin the third quarter of 2021 as compared with $4.2 millionfor the same quarter in 2020;
- Sales and Marketing expenses were
$16.5 millionin the third quarter of 2021 as compared to $12.6 millionfor the same quarter in 2020, representing a 30.8% increase;
- General and Administrative expenses were
$16.9 millionin the third quarter of 2021 as compared to $10.5 millionfor the same quarter in 2020, representing a 60.4% increase; and
- Total Operating Expenses were
$45.1 millionin the third quarter of 2021 as compared with $27.3 millionfor the same quarter in 2020, representing a 64.9% increase.
Clinical Development and Recent Updates
The American Academy of Sleep Medicinepublished an updated clinical practice guideline which includes WAKIX as a recommended treatment option for adults living with narcolepsy. The new clinical practice guideline was published in the Journal of Clinical Sleep Medicinein a special article titled, "Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicineclinical practice guideline." The new guideline updates and replaces the previous AASM guideline published in 2007, and now includes WAKIX as a strong recommendation for the treatment of narcolepsy in adults based on data that showed clinically significant improvement in excessive daytime sleepiness (EDS) and cataplexy in patients treated with WAKIX.
- Enrollment continues in Harmony’s Phase 2 proof of concept clinical trial evaluating the safety and efficacy of pitolisant for the treatment of EDS and other symptoms in patients with PWS with top line data anticipated in the first half of 2022.
- Our Phase 2 proof of concept clinical trial to evaluate the safety and efficacy of pitolisant for EDS and other non-muscular symptoms in adult patients with type 1 myotonic dystrophy (DM1) is advancing with additional clinical sites being activated during Q3. Top-line results are anticipated in the second half of 2022.
August 2021, Harmony acquired HBS-102 (formerly CSTI-100), a potential first-in-class molecule with a novel mechanism of action.
Conference Call Today at
We are hosting our third quarter 2021 financial results conference call and webcast today beginning at
Non-GAAP Financial Measures
In addition to our GAAP results, we provide certain non-GAAP metrics including adjusted net income and adjusted net income per share. We believe that the presentation of these measures provides important supplemental information to management and investors regarding our performance. These measurements are not a substitute for GAAP measurements, and the manner in which we calculate adjusted net income and adjusted net income per share may not be identical to the manner in which other companies calculate adjusted net income and adjusted net income per share. Company management uses these non-GAAP measurements as an aid in monitoring our ongoing financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against comparable companies.
These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with our consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that we may exclude for purposes of its non-GAAP financial measures; and we may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures.
About WAKIX® (pitolisant) Tablets
WAKIX, a first-in-class medication, is approved by the
Indications and Usage
WAKIX is indicated for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy.
Important Safety Information
WAKIX is contraindicated in patients with known hypersensitivity to pitolisant or any component of the formulation. Anaphylaxis has been reported. WAKIX is also contraindicated in patients with severe hepatic impairment.
Warnings and Precautions
WAKIX prolongs the QT interval; avoid use of WAKIX in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval. Avoid use in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval.
The risk of QT prolongation may be greater in patients with hepatic or renal impairment due to higher concentrations of pitolisant; monitor these patients for increased QTc. Dosage modification is recommended in patients with moderate hepatic impairment and moderate or severe renal impairment (see full prescribing information). WAKIX is not recommended in patients with end-stage renal disease (ESRD).
In the placebo-controlled clinical trials conducted in patients with narcolepsy with or without cataplexy, the most common adverse reactions (≥5% and twice placebo) for WAKIX were insomnia (6%), nausea (6%), and anxiety (5%). Other adverse reactions that occurred at ≥2% and more frequently than in patients treated with placebo included headache, upper respiratory infection, musculoskeletal pain, heart rate increased, hallucinations, irritability, abdominal pain, sleep disturbance, decreased appetite, cataplexy, dry mouth, and rash.
Concomitant administration of WAKIX with strong CYP2D6 inhibitors increases pitolisant exposure by 2.2-fold. Reduce the dose of WAKIX by half.
Concomitant use of WAKIX with strong CYP3A4 inducers decreases exposure of pitolisant by 50%. Dosage adjustments may be required (see full prescribing information).
H1 receptor antagonists that cross the blood-brain barrier may reduce the effectiveness of WAKIX. Patients should avoid centrally acting H1 receptor antagonists.
WAKIX is a borderline/weak inducer of CYP3A4. Therefore, reduced effectiveness of sensitive CYP3A4 substrates may occur when used concomitantly with WAKIX. The effectiveness of hormonal contraceptives may be reduced when used with WAKIX and effectiveness may be reduced for 21 days after discontinuation of therapy.
Use in Specific Populations
WAKIX may reduce the effectiveness of hormonal contraceptives. Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with WAKIX and for at least 21 days after discontinuing treatment.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to WAKIX during pregnancy. Patients should be encouraged to enroll in the WAKIX pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call 1-800-833-7460. The safety and effectiveness of WAKIX have not been established in patients less than 18 years of age.
WAKIX is extensively metabolized by the liver. WAKIX is contraindicated in patients with severe hepatic impairment. Dosage adjustment is required in patients with moderate hepatic impairment.
WAKIX is not recommended in patients with end-stage renal disease. Dosage adjustment of WAKIX is recommended in patients with moderate or severe renal impairment.
Dosage reduction is recommended in patients known to be poor CYP2D6 metabolizers; these patients have higher concentrations of WAKIX than normal CYP2D6 metabolizers.
Please see the Full Prescribing Information for WAKIX for more information.
To report suspected adverse reactions, contact
HBS-102, an investigational compound, is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It has the potential to be a first-in-class molecule with a novel mechanism of action that could offer a new approach to the treatment of a variety of rare neurological diseases.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our product WAKIX. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our commercialization efforts and strategy for WAKIX; the rate and degree of market acceptance and clinical utility of WAKIX, pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved; our research and development plans, including our plans to explore the therapeutic potential of pitolisant in additional indications; our ongoing and planned clinical trials; our ability to expand the scope of our license agreement with
HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARY
UNAUDITED CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(In thousands, except share and per share data)
|Three Months Ended
||Nine Months Ended
|Net product revenues||$||80,732||$||45,609||$||214,227||$||103,454|
|Cost of product sold||14,604||7,890||37,701||17,820|
|Research and development||11,739||4,230||22,916||11,829|
|Sales and marketing||16,480||12,601||49,009||38,297|
|General and administrative||16,856||10,508||45,704||26,280|
|Total operating expenses||45,075||27,339||117,629||76,406|
|Loss on debt extinguishment||(26,146||)||—||(26,146||)||(22,639||)|
|Other income (expense), net||—||(1,525||)||(15||)||(3,071||)|
|Interest expense, net||(5,429||)||(6,946||)||(19,783||)||(20,254||)|
|(Loss) income before income taxes||(10,522||)||1,909||12,953||(36,736||)|
|Income tax benefit (expense)||902||—||(1,070||)||—|
|Net (loss) income and comprehensive (loss) income||$||(9,620||)||$||1,909||$||11,883||$||(36,736||)|
|Accumulation of dividends on preferred stock||—||(6,013||)||—||(26,904||)|
|Net (loss) income available to common stockholders||$||(9,620||)||$||(4,104||)||$||11,883||$||(63,640||)|
|(LOSS) EARNINGS PER SHARE:|
|Weighted average number of shares of common stock - basic||57,722,163||30,212,959||57,188,101||15,324,362|
|Weighted average number of shares of common stock - diluted||57,722,163||30,212,959||58,776,158||15,324,362|
CONSOLIDATED BALANCE SHEETS
(In thousands except share and per share data)
|Cash and cash equivalents||$||189,704||$||228,631|
|Trade receivables, net||33,206||22,176|
|Other current assets||3,183||1,302|
|Total current assets||240,691||262,891|
|Property and equipment, net||937||938|
|Intangible assets, net||148,562||162,343|
|Other noncurrent assets||152||152|
|Total noncurrent assets||150,401||164,183|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Current portion of long term debt||2,000||—|
|Other current liabilities||436||314|
|Total current liabilities||47,623||134,539|
|Long term debt, net||190,069||194,250|
|Other noncurrent liabilities||1,382||1,105|
|Total noncurrent liabilities||191,451||195,355|
|COMMITMENTS AND CONTINGENCIES (Note 9)|
|Preferred stock -
|Common stock—$0.00001 par value; 500,000,000 shares authorized at
|Additional paid in capital||628,329||585,374|
|TOTAL STOCKHOLDERS’ EQUITY||152,018||97,180|
|TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY||$||391,092||$||427,074|
RECONCILIATION OF GAAP TO NON-GAAP RESULTS
(In thousands except share and per share data)
|Three Months Ended
||Nine Months Ended
|Net (loss) income||$||(9,620||)||$||1,909||$||11,883||$||(36,736||)|
|Additional Non-GAAP Adjustments:|
|Stock-based compensation expense||4,664||1,330||11,722||2,266|
|Loss on debt extinguishment||26,146||—||26,146||22,639|
|Non-GAAP adjusted net income (loss)||$||30,389||$||13,677||$||84,684||$||17,386|
|Accumulation of yield on preferred stock||—||(6,013||)||—||(26,904||)|
|Non-GAAP adjusted net income (loss) available to common stockholders||30,389||7,664||84,684||(9,518||)|
|GAAP reported net income (loss) per diluted share||$||(0.17||)||$||(0.14||)||0.20||$||(4.15||)|
|Non-GAAP adjusted net income (loss) per diluted share||$||0.51||$||0.25||1.44||$||(0.62||)|
|Weighted average number of shares of common stock used in non-GAAP diluted per share (1)||59,270,603||30,212,959||58,776,158||15,324,362|
Harmony Biosciences Investor Contact:
Harmony Biosciences Media Contact:
Source: Harmony Biosciences